<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName JATS-archivearticle1.dtd?><?SourceDTD.Version 1.1?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">PLoS One</journal-id><journal-id journal-id-type="iso-abbrev">PLoS ONE</journal-id><journal-id journal-id-type="publisher-id">plos</journal-id><journal-id journal-id-type="pmc">plosone</journal-id><journal-title-group><journal-title>PLoS ONE</journal-title></journal-title-group><issn pub-type="epub">1932-6203</issn><publisher><publisher-name>Public Library of Science</publisher-name><publisher-loc>San Francisco, USA</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">3617223</article-id><article-id pub-id-type="pmid">23593180</article-id><article-id pub-id-type="publisher-id">PONE-D-12-38805</article-id><article-id pub-id-type="doi">10.1371/journal.pone.0060237</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Biology</subject><subj-group><subject>Genetics</subject><subj-group><subject>Human Genetics</subject><subj-group><subject>Genetic Association Studies</subject></subj-group></subj-group><subj-group><subject>Population Genetics</subject><subj-group><subject>Genetic Polymorphism</subject></subj-group></subj-group><subj-group><subject>Genetic Mutation</subject><subject>Genetics of Disease</subject></subj-group></subj-group><subj-group><subject>Immunology</subject><subj-group><subject>Immune System</subject><subj-group><subject>Complement System</subject></subj-group></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Mathematics</subject><subj-group><subject>Statistics</subject><subj-group><subject>Biostatistics</subject></subj-group></subj-group></subj-group><subj-group subj-group-type="Discipline-v2"><subject>Medicine</subject><subj-group><subject>Clinical Research Design</subject><subj-group><subject>Cohort Studies</subject></subj-group></subj-group><subj-group><subject>Infectious Diseases</subject><subj-group><subject>Neglected Tropical Diseases</subject><subj-group><subject>Chagas Disease</subject></subj-group></subj-group><subj-group><subject>Parasitic Diseases</subject><subj-group><subject>Chagas Disease</subject></subj-group></subj-group></subj-group></subj-group></article-categories><title-group><article-title>Association of L-Ficolin Levels and <italic>FCN2</italic> Genotypes with Chronic Chagas Disease</article-title><alt-title alt-title-type="running-head">Association of L-Ficolin Levels and Chagas Disease</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Luz</surname><given-names>Paola R.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Boldt</surname><given-names>Angelica B. W.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Grisbach</surname><given-names>Caroline</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name><surname>Kun</surname><given-names>J&#252;rgen F. J.</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Velavan</surname><given-names>Thirumalaisamy P.</given-names></name><xref ref-type="aff" rid="aff2">
<sup>2</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Messias-Reason</surname><given-names>Iara J. T.</given-names></name><xref ref-type="aff" rid="aff1">
<sup>1</sup>
</xref><xref ref-type="corresp" rid="cor1">
<sup>*</sup>
</xref></contrib></contrib-group><aff id="aff1">
<label>1</label>
<addr-line>Laborat&#243;rio de Imunopatologia Molecular &#8211; Departamento de Patologia M&#233;dica, Hospital de Cl&#237;nicas, Universidade Federal do Paran&#225;, Curitiba, Brazil</addr-line>
</aff><aff id="aff2">
<label>2</label>
<addr-line>Institute of Tropical Medicine, University of Tuebingen, Tuebingen, Germany</addr-line>
</aff><contrib-group><contrib contrib-type="editor"><name><surname>Rooijakkers</surname><given-names>Suzan H. M.</given-names></name><role>Editor</role><xref ref-type="aff" rid="edit1"/></contrib></contrib-group><aff id="edit1">
<addr-line>University Medical Center Utrecht, The Netherlands</addr-line>
</aff><author-notes><corresp id="cor1">* E-mail: <email>velavan@medizin.uni-tuebingen.de</email> (TPV); <email>iarareason@hc.ufpr.br</email> (IJTMR)</corresp><fn fn-type="COI-statement"><p><bold>Competing Interests: </bold>The authors have declared that no competing interests exist.</p></fn><fn fn-type="con"><p>Conceived and designed the experiments: IJTMR TPV JFJK. Performed the experiments: PRL ABWB CG. Analyzed the data: ABWB TPV PRL. Contributed reagents/materials/analysis tools: TPV IJTMR. Wrote the paper: PRL ABWB TPV IJTMR.</p></fn></author-notes><pub-date pub-type="collection"><year>2013</year></pub-date><pub-date pub-type="epub"><day>4</day><month>4</month><year>2013</year></pub-date><volume>8</volume><issue>4</issue><elocation-id>e60237</elocation-id><history><date date-type="received"><day>11</day><month>12</month><year>2012</year></date><date date-type="accepted"><day>23</day><month>2</month><year>2013</year></date></history><permissions><copyright-statement>&#169; 2013 Luz et al</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Luz et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.</license-p></license></permissions><abstract><sec><title>Background</title><p>L-ficolin (encoded by <italic>FCN2</italic>) binds to acetylated sugar moieties of many pathogens, including <italic>Trypanosoma cruzi</italic>, promoting their phagocytosis and lysis by the complement system.</p></sec><sec><title>Methods</title><p>We investigated L-ficolin levels in 160 <italic>T. cruzi</italic> infected patients with chronic Chagas disease and 71 healthy individuals, and <italic>FCN2</italic> polymorphisms (&#8722;<italic>986 G&gt;A</italic>, <italic>&#8722;602 G&gt;A</italic>, and <italic>&#8722;4 A&gt;G</italic> in the promoter and <italic>A258S</italic> in exon 8) in 243 patients, being 88 indeterminate (asymptomatic), 96 with cardiac, 23 with digestive and 33 with cardiodigestive manifestations (two were unspecified) and 305 controls (135 for <italic>A258S</italic>).</p></sec><sec><title>Results</title><p>Patients presented lower L-ficolin plasma levels than controls (p&lt;0.0001). Among the different groups of cardiac commitment, individuals with moderate forms had higher L-ficolin levels than the severe forms (P&#8202;=&#8202;0.039). Lower L-ficolin levels were found associated with the <italic>258S</italic> variant in the patients (P&#8202;=&#8202;0.034). We found less <italic>&#8722;4A/G</italic> heterozygotes in the cardiac patients, than in the controls (OR&#8202;=&#8202;0.56 [95% CI&#8202;=&#8202;0.33&#8211;0.94], P&#8202;=&#8202;0.034). Heterozygote <italic>&#8722;4A/G</italic> genotypes with the <italic>258S</italic> variant and <italic>258SS</italic> homozygotes were nevertheless more frequent among cardiodigestive patients than in controls (OR&#8202;=&#8202;14.1 [95% CI&#8202;=&#8202;3.5&#8211;56.8], P&#8202;=&#8202;0.0001) and in indeterminate patients (OR&#8202;=&#8202;3.2 [95% CI&#8202;=&#8202;1.1&#8211;9.4], P&#8202;=&#8202;0.037). We also found an association of the allelic frequency of the <italic>258S</italic> variant with cardiodigestive Chagas disease compared to controls (OR&#8202;=&#8202;2.24 [95% CI&#8202;=&#8202;1.1&#8211;4.5], P&#8202;=&#8202;0.037). Thus, decreased patient levels of L-ficolin reflect not only protein consumption due to the disease process, but also the higher frequency of the <italic>258S</italic> variant in patients with cardiodigestive symptoms.</p></sec><sec><title>Conclusion</title><p>The very first study on Brazilian cohort associates both L-ficolin plasma levels and <italic>FCN2</italic> variants to Chagas disease and subsequent disease progression. The prognostic value of L-ficolin levels and the <italic>FCN2*A258S</italic> polymorphism should be further evaluated in other settings.</p></sec></abstract><funding-group><funding-statement>This study was supported by CNPq, CAPES and DAAD (Deutscher Akademischer Austausch Dienst), who provided a scholarship for PRL. This study was also supported by grant from Bundesministeriums f&#252;r Bildung und Forschung (BMBF 01DN11001-BRA11/A33) to TP Velavan. The authors acknowledge the support by the Deutsche Forschungsgemeinschaft (DFG) and Open Access Publishing Fund of Tuebingen University. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.</funding-statement></funding-group><counts><page-count count="8"/></counts></article-meta></front><body><sec id="s1"><title>Introduction</title><p>Chagas disease (CD) occurs in 18 different countries, mostly throughout South and Central America, and affects approximately 15 million people worldwide <xref rid="pone.0060237-Dias1" ref-type="bibr">[1]</xref>. CD pathogenesis, caused by the flagellated protozoan <italic>Trypanosoma cruzi</italic>, is still poorly understood and there is no available marker that indicates the progression to the different clinical forms or prognosis of chronic disease. Despite the fact that approximately 50% of the individuals infected by <italic>T. cruzi</italic> stay in the indeterminate or asymptomatic form throughout their lives, which in general present good prognosis, each year about 2&#8211;5% of them progress to symptomatic forms of the disease, presenting irreversible cardiac and/or digestive and/or disorders <xref rid="pone.0060237-Ribeiro1" ref-type="bibr">[2]</xref>. A plausible presumption is that individuals who remain asymptomatic are able to reduce parasite numbers in the early phase of infection, and down modulate the immune response, limiting the development of pathology. On the other hand, individuals who will develop cardiac disease, although capable of parasite control, may not be capable of mounting efficient immunoregulatory mechanisms, thus leading to establishment of persistent inflammation <xref rid="pone.0060237-Dutra1" ref-type="bibr">[3]</xref>.</p><p>The complement system has been shown to play an important role in the control of experimental <italic>T. cruzi</italic> infection, as well in clinical evolution of CD <xref rid="pone.0060237-Kipnis1" ref-type="bibr">[4]</xref>&#8211;<xref rid="pone.0060237-Boldt1" ref-type="bibr">[8]</xref>. Ficolins are pattern-recognition proteins which bind to specific pathogen-associated molecular patterns (PAMP) on microorganism surfaces, promoting activation of the complement cascade through the lectin pathway thereby triggering the innate immune response <xref rid="pone.0060237-Runza1" ref-type="bibr">[9]</xref>. Other putative functions of ficolins include binding to late apoptotic cells, apoptotic bodies and necrotic cells, enhancing their uptake by macrophages <xref rid="pone.0060237-Jensen1" ref-type="bibr">[10]</xref>. The ficolins are synthesized as a single polypeptide containing N-collagen-tails and C-terminal fibrinogen-like binding domains, which are oligomerized into higher oligomeric forms <xref rid="pone.0060237-Runza1" ref-type="bibr">[9]</xref>. In humans, three ficolin genes have been identified: <italic>FCN1</italic>, <italic>FCN2</italic> and <italic>FCN3</italic>, which encode M-ficolin (ficolin-1), L-ficolin (ficolin-2) and H-ficolin (Hakata antigen or ficolin-3), respectively. Single nucleotide polymorphisms (SNPs) in the promoter region of the <italic>FCN2</italic> gene have been associated with the variability in the individual serum concentrations of the protein. Studies have shown that the presence of the nucleotide adenine (<italic>A</italic>) at positions &#8722;986 A&gt;G and &#8722;602 A&gt;G as well as the nucleotide guanine (<italic>G</italic>) at the position &#8722;4G&gt;A are related to higher L-ficolin serum levels <xref rid="pone.0060237-Hummelshoj1" ref-type="bibr">[11]</xref>. In addition, two polymorphisms located in exon 8, encoding the fibrinogen-like domain (containing <italic>T236M</italic> and <italic>A258S</italic>) are associated with decreased and increased ability of binding to acetylated residues, respectively <xref rid="pone.0060237-Hummelshoj1" ref-type="bibr">[11]</xref>&#8211;<xref rid="pone.0060237-MuntheFog1" ref-type="bibr">[13]</xref>. L-ficolin levels and <italic>FCN2</italic> polymorphisms have been reported to be associated with different diseases <xref rid="pone.0060237-deMessiasReason1" ref-type="bibr">[14]</xref>&#8211;<xref rid="pone.0060237-Swierzko1" ref-type="bibr">[20]</xref>.</p><p>Both L-ficolin and H-ficolin are able to interact with the mannan-binding lectin (MBL)-associated serine proteases, promoting activation of the complement cascade <xref rid="pone.0060237-Matsushita1" ref-type="bibr">[21]</xref>. L-ficolin recognizes N-acetylated molecules, including N-acetylglucosamine (GlcNAc) or N-acetylgalactosamine (GalNAc) <xref rid="pone.0060237-Krarup1" ref-type="bibr">[22]</xref>, <xref rid="pone.0060237-Krarup2" ref-type="bibr">[23]</xref>. The surface of <italic>T. cruzi</italic> contains a large diversity of N-linked and O-linked carbohydrate-rich molecules and it was recently demonstrated that <italic>T. cruzi</italic> activates the lectin pathway <xref rid="pone.0060237-Cestari1" ref-type="bibr">[7]</xref>. The authors have shown that a fast binding of L-ficolin occurs on the surface of <italic>T. cruzi</italic> and that the depletion of these molecules in the serum leads to failure of parasite clearance by the complement, indicating that the lectin pathway obviously plays an important role in host defense against this pathogen. Although it has been demonstrated that L-ficolin is involved in the host defense against <italic>T. cruzi</italic> infection, there are no studies on ficolins and chronic CD so far. In this study we aim to evaluate whether L-ficolin levels and <italic>FCN2</italic> polymorphisms could be possible prognostic markers for susceptibility to the different clinical forms of CD.</p></sec><sec sec-type="materials|methods" id="s2"><title>Materials and Methods</title><sec id="s2a"><title>Ethics Statement</title><p>Formal written consent approved by the ethics committee was obtained from each individual. The project was approved by the ethics committee of Hospital De Clinicas, Universidade Federal do Parana (CEP/HC-UFPR n.1457.122/2007-06).</p></sec><sec id="s2b"><title>Subjects and Samples</title><p>A total of 243 chronic CD patients attended at the Chagas Disease Ambulatory of the Clinical Hospital of the Federal University of Paran&#225; (HC- UFPR) were investigated (Mean age 57.3 [34&#8211;90] years; 58% female, 42% male; 76.5% Euro-Brazilian, 18.9% Afro-Brazilian, 4.1% Amerindian, 0.5% Asian). CD diagnosis was performed by serological and clinical examinations. The clinical history of the patients was obtained from medical records and interviews, using a standard questionnaire. Patients younger than 18 years-old, with a history of blood transfusion, recent infections or suspected non-chagasic cardiomyopathy (such as hypertensive cardiopathy) were excluded. The cardiac patients were graded according to the cardiac insufficiency classification of the American Heart Association (AHA), adapted for Chagas disease <xref rid="pone.0060237-BrazilianConsensusonChagas1" ref-type="bibr">[24]</xref>. Detailed demographic and clinical characteristics of the specific CD forms are given in <xref ref-type="table" rid="pone-0060237-t001">Table 1</xref>. A group of 305 unrelated South Brazilians with negative Chagas (anti-<italic>Trypanosoma cruzi</italic>) serology and without non-chagasic cardiomyopathy were used as controls (Mean age 41 [18&#8211;75] years; 49.2% female, 50.8% male; 85.2% Euro-Brazilian, 12.8% Afro-Brazilian, 1.3% Amerindian, 0.7% Asian). Ethnic background of patients and controls was determined as previously described <xref rid="pone.0060237-Boldt2" ref-type="bibr">[25]</xref>.</p><table-wrap id="pone-0060237-t001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0060237.t001</object-id><label>Table 1</label><caption><title>Demographic and clinical parameters of chronic Chagas patients.</title></caption><alternatives><graphic id="pone-0060237-t001-1" xlink:href="pone.0060237.t001"/></alternatives><table-wrap-foot><fn id="nt101"><label>*</label><p>MBL levels were determined by ELISA and C-reactive protein (hs-CRP) by nephelometry as previously described <xref rid="pone.0060237-Luz1" ref-type="bibr">[6]</xref> n number of investigated samples; N.d. not determined.</p></fn><fn id="nt102"><label>&amp;</label><p>some patients were unspecified.</p></fn></table-wrap-foot></table-wrap><p>After signing the informed formal written consent, three ml of venous blood from each individual was collected in tubes containing ethylenediamine tetra-acetic acid (EDTA). Samples were maintained on ice after collection and during transportation to the laboratory. After centrifugation at &#8722;4&#176;C plasma separation from whole blood was performed as quickly as possible, samples were aliquoted on ice and immediately stored at &#8722;80&#176;C until used. Genomic DNA was extracted from peripheral whole blood using commercial kits (GFX&#8482; Genomic Blood DNA Purification Kit, GE Healthcare, S&#227;o Paulo, Brazil), according to the manufacturer&#8217;s instructions.</p></sec><sec id="s2c"><title>L-fciolin Measurement</title><p>The quantification of plasma L-ficolin levels was performed in 71 controls (of which 62 were genotyped) and 160 patients (of which 158 were genotyped, being 54 indeterminate, 54 with some kind of cardiomyopathy, 19 with digestive symptoms, 29 with the cardiodigestive form and two unspecified). L-ficolin levels were determined using a commercially available enzyme linked immunosorbent assay (ELISA) kit (HK336, Hycult&#174; Biotech, Uden, Netherlands), according to the manufacturer&#8217;s instructions. The detecting range of this kit is 16&#8211;1000 ng/ml of the protein.</p></sec><sec id="s2d"><title>Genotyping of <italic>FCN2</italic> Variants</title><p>Three promoter SNPs including <italic>&#8722;986 G&gt;A</italic> (rs3124952), <italic>&#8722;602 G&gt;A</italic> (rs3124953), <italic>&#8722;4 A&gt;G</italic> (rs17514136) and <italic>A258S</italic> in exon 8 (rs7851696) were genotyped in the patients using Fluorescence Resonance Energy Transfer (FRET) based real-time PCR assay as previously described <xref rid="pone.0060237-Ojurongbe1" ref-type="bibr">[26]</xref>, and in 135 controls through sequencing <xref rid="pone.0060237-deMessiasReason1" ref-type="bibr">[14]</xref>. Additionally, 170 patients were genotyped for the SNPs &#8722;986 G&gt;A (rs3124952), &#8722;602 G&gt;A (rs3124953) and &#8722;4 A&gt;G (rs17514136) using PCR amplification with sequence-specific primers (SSP) (<xref ref-type="table" rid="pone-0060237-t002">Table 2</xref>). In order to reconstruct the haplotypes, we performed three reactions called FCN2 Prom12, FCN2 Prom23 and FCN2Prom13, using the primers listed in <xref ref-type="table" rid="pone-0060237-t002">table 2</xref>. In order to validate the reactions, we added two generic primers, either HGHf and HGHr or FCN2Ex8f and FCN2Ex8r. PCR amplifications were carried out in a Therm-2000 (Axygen, United States) or MJ96+ (Biocycler, China) research thermocyclers with 20 ng DNA, 0.2 mM dNTP (Invitrogen Life Technologies, United States), 0.2 &#181;M of each primer (Invitrogen Life Technologies, United States), 1X Coral Load PCR buffer (Qiagen, The Netherlands), 2 mM of MgCl2 (Invitrogen Life Technologies, United States), 0.35&#8211;0.7 mM of Q solution (Invitrogen Life Technologies, United States), and 0.15 U Taq DNA polymerase (Invitrogen Life Technologies or Promega, United States) in a final volume of 15 &#181;l. After a 5 min initial DNA denaturation step at 94&#176;C, the PCR protocol was followed by 30 cycles of 30 sec at 94&#176;C, 45 sec at the specific annealing temperature and 40 sec at 72&#176;C, ending with 5 min at 72&#176;C in the final DNA extension step. A touch-down strategy decreasing the annealing temperatures every 10 cycles was performed, using 68&#176;C-64&#176;C-62&#176;C for FCN2 Prom12, 65&#176;C-62&#176;C-59&#176;C for FCN2 Prom23 and 69&#176;C-67&#176;C-65&#176;C for FCN2Prom13. According to a previous study, this strategy assures higher specificity to the amplification and provides a larger amount of the desired PCR product <xref rid="pone.0060237-Boldt3" ref-type="bibr">[27]</xref>. The promoter haplotypes amplified by a pair of SSPs were identified by the presence or absence of specific bands when run on a 1.2% agarose gel electrophoresis. Positive controls reassured the quality of the reactions.</p><table-wrap id="pone-0060237-t002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0060237.t002</object-id><label>Table 2</label><caption><title>Primers used in the sequence-specific PCR (PCR-SSP) for the &#8722;986, &#8722;602 and &#8722;4 promoter <italic>FCN2</italic> polymorphisms.</title></caption><alternatives><graphic id="pone-0060237-t002-2" xlink:href="pone.0060237.t002"/></alternatives><table-wrap-foot><fn id="nt103"><label/><p>Primer design was based on the NT_019501 reference sequence. FCN2&#8211; Ficolin 2; HGH &#8211; Human Growth Hormone; f &#8211; forward; r &#8211; reverse; In bold: variant nucleotides; bp &#8211; base pairs; Prom &#8211; promoter; Ex8&#8211; exon 8.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s2e"><title>Statistical Analysis</title><p>Statistics was done using the statistical package for social sciences (SPSS) version 10.0, STATA ver 9.1 and with the Graphpad Prism 5.04 software package. Data were normalized and have been analyzed by STATA. Genotype and allele frequencies were obtained by direct counting. The hypothesis of Hardy&#8211;Weinberg equilibrium and of homogeneity between genotype distributions (exact test of population differentiation of Raymond and Rousset) were executed with the ARLEQUIN software package version 3 <xref rid="pone.0060237-Excoffier1" ref-type="bibr">[28]</xref>. Possible associations between <italic>FCN2</italic> genotypes/haplotypes/variants and different clinical forms were analyzed with two tailed Fisher&#8217;s exact test. Additionally multivariate analysis was executed to validate whether variables such as age, gender and ethnicity may possibly influence the clinical outcome by MANOVA. L-ficolin concentrations in the different groups were presented by the median and range and compared between the genotypes using either nonparametric Mann-Whitney or Kruskal-Wallis tests. Also correlation between L-ficolin levels to age was tested using spearman&#8217;s rank correlation. Unless otherwise stated, two-tailed P-values less than 5% were considered significant. <italic>P-</italic>values for correlations are provided after correction for false detection rate (FDR).</p></sec></sec><sec id="s3"><title>Results</title><sec id="s3a"><title>L-ficolin Levels</title><p>Higher L-ficolin plasma concentrations were observed in the controls when compared to Chagas patients (median: 4252 ng/ml vs. 2538 ng/ml, P&lt;0.0001). Similar trend was observed between indeterminate and symptomatic patients (median: 2888 ng/ml vs. 2519 ng/ml, one-tailed P&#8202;=&#8202;0.051, two-tailed P&#8202;=&#8202;0.10) (<xref ref-type="fig" rid="pone-0060237-g001">Figure 1</xref>). No significant correlation between L-ficolin levels and age has been observed using Spearman&#8217;s rank correlation test (Spearman&#8217;s rho&#8202;=&#8202;&#8722;0.1402, p&#8202;=&#8202;0.08). Nevertheless L-ficolin levels were higher in the group with 45 to 59 years of age, compared with those aged above 60 years (median: 2834 ng/ml vs. 2265 ng/ml, P&#8202;=&#8202;0.005). Nevertheless they were still lower than the levels found in the 45&#8211;59 years group of controls, which had a median of 4311 ng/ml (P&#8202;=&#8202;0.0007) (<xref ref-type="fig" rid="pone-0060237-g002">Figure 2</xref>). There was also a trend to increased L-ficolin concentration in the healthy adults (P&#8202;=&#8202;0.072). Among the different groups of cardiac commitment, individuals with the less severe B form had higher L-ficolin levels than the C and D forms (median: 2981 ng/ml vs. 2094 ng/ml, P&#8202;=&#8202;0.039) (<xref ref-type="fig" rid="pone-0060237-g002">Figure 2</xref>). Among the clinical parameters (listed in <xref ref-type="table" rid="pone-0060237-t001">Table 1</xref>), only mannose-binding lectin correlated weakly with L-ficolin levels in the indeterminate patients (R2&#8202;=&#8202;0.38, P&#8202;=&#8202;0.004), but not in the other disease stages (not shown). Tests for multivariate analysis revealed no significant effects of age, gender or ethnicity to L-ficolin levels.</p><fig id="pone-0060237-g001" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0060237.g001</object-id><label>Figure 1</label><caption><title>L-ficolin levels in Chagas patients and controls.</title><p>The statistical distribution is shown with median (line in the box), box indicating the 25&#8211;75 percentiles, whiskers the 5&#8211;95 percentile and arithmetic mean (cross inside the box).</p></caption><graphic xlink:href="pone.0060237.g001"/></fig><fig id="pone-0060237-g002" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0060237.g002</object-id><label>Figure 2</label><caption><title>Distribution of L-ficolin levels based on age and clinical classification.</title><p>(A) L-ficolin levels in Chagas patients and controls according to age (B) L-ficolin levels in Chagas patients and controls based on class of cardiac commitment. The statistical distribution is shown with median and interquartile range. One outlier (18880.7 ng/ml) was excluded for better visualization in the 45&#8211;59 group of patients.</p></caption><graphic xlink:href="pone.0060237.g002"/></fig></sec><sec id="s3b"><title>
<italic>FCN2</italic> Polymorphisms</title><p>Five haplotypes comprehending the &#8722;<italic>986 G&gt;A,</italic> &#8722;<italic>602 G&gt;A,</italic> &#8722;<italic>4 A&gt;G</italic> variants in the promoter and the amino acid substitution <italic>A258S</italic> in exon 8 were identified: <italic>AAAA</italic>, <italic>AGAA</italic>, <italic>AGGA, GGAA</italic> and <italic>GGAS</italic> (<xref ref-type="table" rid="pone-0060237-t003">Table 3</xref>). Haplotype distributions did not differ between the different group and genotype distributions were in Hardy Weinberg equilibrium. Nevertheless we observed less &#8722;<italic>4A/G</italic> heterozygotes (comprehending the promoter genotypes <italic>AAA/AGG, AGA/AGG</italic> and <italic>AGG/GGA</italic>) in the cardiac patients than in the controls (23/96 or 24% vs. 110/305 or 36.1%, OR&#8202;=&#8202;0.56 [95% CI&#8202;=&#8202;0.33&#8211;0.94], P&#8202;=&#8202;0.034), and there was also a trend in the same direction between cardiac and indeterminate patients (P&#8202;=&#8202;0.077) (<xref ref-type="table" rid="pone-0060237-t003">Table 3</xref>). Heterozygote &#8722;<italic>4A/G</italic> genotypes with the <italic>258S</italic> variant in exon 8 (<italic>AGGA/GGAS</italic>) and <italic>258S</italic> homozygotes (<italic>GGAS/GGAS</italic>) were more frequent among cardiodigestive patients, than in controls (8/33 or 24.2% vs. 3/135 or 2.22%, respectively, OR&#8202;=&#8202;14.1 [95% CI&#8202;=&#8202;3.5&#8211;56.8], P&#8202;=&#8202;0.0001) and in indeterminate patients (8/33 or 24.2% vs. 8/88 or 9.1%, OR&#8202;=&#8202;3.2 [95% CI&#8202;=&#8202;1.1&#8211;9.4], P&#8202;=&#8202;0.037). We also found an association of the allelic frequency of the <italic>258S</italic> variant with cardiodigestive Chagas disease (14/66 or 21.2% vs. 29/270 or 10.7% in the controls, OR&#8202;=&#8202;2.24 [95%CI&#8202;=&#8202;1.1&#8211;4.5], P&#8202;=&#8202;0.037) (<xref ref-type="table" rid="pone-0060237-t003">Tables 3</xref> and <xref ref-type="table" rid="pone-0060237-t004">4</xref>).</p><table-wrap id="pone-0060237-t003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0060237.t003</object-id><label>Table 3</label><caption><title>
<italic>FCN2</italic> allele and haplotype frequencies (&#177; standard deviation) in Chagas patients and controls.</title></caption><alternatives><graphic id="pone-0060237-t003-3" xlink:href="pone.0060237.t003"/></alternatives><table-wrap-foot><fn id="nt104"><label/><p>In bold: significant difference (see text).</p></fn><fn id="nt105"><label>*</label><p>
<italic>A258S</italic> was investigated by sequencing in a subset of 135 samples. N number of chromosomes.</p></fn></table-wrap-foot></table-wrap><table-wrap id="pone-0060237-t004" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0060237.t004</object-id><label>Table 4</label><caption><title>
<italic>FCN2</italic> genotype frequencies (%) in Chagas patients and controls.</title></caption><alternatives><graphic id="pone-0060237-t004-4" xlink:href="pone.0060237.t004"/></alternatives><table-wrap-foot><fn id="nt106"><label/><p>In bold: genotypes with &#8722;<italic>4 A/G</italic> heterozygosity, whose summed frequencies differ between cardiac patients and controls. Gray-shadowed: genotypes <italic>AGGA/GGAS</italic> and <italic>GGAS/GGAS</italic> (homozygote for <italic>A258S</italic>), whose summed frequencies differ between cardiodigestive patients and indeterminate patients or controls (see text).</p></fn><fn id="nt107"><label>*</label><p>
<italic>A258S</italic> was investigated by sequencing in a subset of 135 controls. n number of individuals.</p></fn></table-wrap-foot></table-wrap></sec><sec id="s3c"><title>Association of L-ficolin Levels with <italic>FCN2</italic> Genotypes</title><p>Lower L-ficolin levels were found associated with the <italic>258S</italic> variant in the patients (median: 2419 ng/ml vs. 2748 ng/ml in genotypes without <italic>258S</italic>, P&#8202;=&#8202;0.034). There was no difference between the levels according to the other genotypes, even in the controls (not shown). Whereas heterozygote genotypes with &#8722;<italic>4 A/G</italic> were, in general, widely distributed according to L-ficolin levels in the different groups, those with <italic>258 S</italic> (genotype <italic>AGGA/GGAS</italic>) as well as <italic>258 S/S</italic> (<italic>GGAS/GGAS</italic>) homozygotes, clearly associated with concentrations under 3000 ng/ml (Wilcoxon signed rank test, P&#8202;=&#8202;0.04) (<xref ref-type="fig" rid="pone-0060237-g003">Figure 3</xref>).</p><fig id="pone-0060237-g003" orientation="portrait" position="float"><object-id pub-id-type="doi">10.1371/journal.pone.0060237.g003</object-id><label>Figure 3</label><caption><title>Distribution of L-ficolin levels based on genotypic variant and disease stages.</title><p>(A) L-ficolin levels in Chagas patients and controls by the presence of <italic>258S</italic> variant and (B) Distribution of L-ficolin levels in Chagas patients and controls by disease stages. The statistical distribution is shown with median and interquartile range. Closed dots: samples with &#8722;<italic>4 A/G</italic> genotype. Closed boxes: samples with &#8722;<italic>4 A/G</italic> and <italic>258A/S</italic> (<italic>AGGA/GGAS</italic> genotype) or <italic>258S/S</italic> homozygotes (<italic>GGAS/GGAS</italic> genotype).</p></caption><graphic xlink:href="pone.0060237.g003"/></fig></sec></sec><sec id="s4"><title>Discussion</title><p>In this study, L-ficolin levels were measured in plasma of the Chagas patients and controls. L-ficolin levels in the controls were within the range reported for healthy European adults in the early studies <xref rid="pone.0060237-Kilpatrick1" ref-type="bibr">[29]</xref>, <xref rid="pone.0060237-Sallenbach1" ref-type="bibr">[30]</xref>. A decreased L-ficolin plasma level were observed in the Chagas patients when compared to controls, and a similar trend was observed between symptomatic patients and indeterminate, however, this difference was not significant. Importantly, serum L-ficolin concentrations were also lower in Bronchiectasis patients than controls from the UK <xref rid="pone.0060237-Kilpatrick1" ref-type="bibr">[29]</xref>. In contrast to our previous work with the same patients, where MBL levels increased gradually according to age, L-ficolin levels were higher in the group with 45 to 59 years of age, compared with those aged above 60 years. There was also a trend to increased L-ficolin concentration in the healthy adults (P&#8202;=&#8202;0.072), but others did not find any relationship between L-ficolin concentration and age in healthy Scottish adults <xref rid="pone.0060237-Kilpatrick1" ref-type="bibr">[29]</xref>. There was no significant difference between L-ficolin levels according to the gender of patients and controls, as expected <xref rid="pone.0060237-Kilpatrick1" ref-type="bibr">[29]</xref>. In addition, the difference of L-ficolin levels was observed among the different groups of cardiac commitment. Of which individuals with the less severe B form had higher L-ficolin levels than the C and D forms. Interestingly, median L-ficolin levels are higher in acute than in chronic hepatitis B conditions <xref rid="pone.0060237-Hoang1" ref-type="bibr">[15]</xref>. They are also higher in acute malaria, compared with the levels after treatment <xref rid="pone.0060237-Faik1" ref-type="bibr">[16]</xref>, but lower in <italic>Schistosoma haematobium</italic>-infected individuals from Nigeria, compared to controls <xref rid="pone.0060237-Ouf1" ref-type="bibr">[17]</xref>. Our results contrast with those found by our group in the same patients regarding MBL levels, which were much higher (above 1000 ng/ml) in patients with chagasic cardiomyopathy and did not differ between the B C and D stages <xref rid="pone.0060237-Luz1" ref-type="bibr">[6]</xref>. Furthermore, a weak correlation between mannose-binding lectin and L-ficolin levels was observed in the indeterminate patients, but not in the other disease stages.</p><p>Allele and haplotype frequencies in the controls did not differ from those reported for European-derived populations <xref rid="pone.0060237-Hummelshoj1" ref-type="bibr">[11]</xref>, <xref rid="pone.0060237-Ojurongbe1" ref-type="bibr">[26]</xref>. No significant difference of haplotype distribution was observed between different groups, nevertheless, &#8722;<italic>4 A/G</italic> heterozygotes was observed to associate with the disease when compared cardiac patients to the controls as well as cardiac to the indeterminate patients. In addition, the <italic>AGG</italic> promoter haplotype, whose presence is obligatory in &#8722;<italic>4 A/G</italic> heterozygotes, was also associated with protection against HBV infection in Vietnamese <xref rid="pone.0060237-Hoang1" ref-type="bibr">[15]</xref>, but with susceptibility to schistosomiasis in Nigeria <xref rid="pone.0060237-Ouf1" ref-type="bibr">[17]</xref>. Our group found the <italic>AGA</italic> haplotype to be associated with protection against clinical leprosy and rheumatic fever <xref rid="pone.0060237-deMessiasReason1" ref-type="bibr">[14]</xref>, <xref rid="pone.0060237-MessiasReason2" ref-type="bibr">[18]</xref>, whereas others found it associated with susceptibility to cutaneous leishmaniasis <xref rid="pone.0060237-Excoffier1" ref-type="bibr">[28]</xref>. Ficolin-2 seems to be, as MBL, a double-edged sword in immunity, explaining the contrasting results in association studies with different infectious diseases. We also found an association of the allelic frequency of the <italic>258S</italic> variant with cardiodigestive Chagas disease (<xref ref-type="table" rid="pone-0060237-t003">Tables 3</xref> and <xref ref-type="table" rid="pone-0060237-t004">4</xref>). The <italic>258S</italic> variant was also found associated by others with earlier onset of <italic>Pseudomonas aeruginosa</italic> colonization in cystic fibrosis patients <xref rid="pone.0060237-Haerynck1" ref-type="bibr">[31]</xref>. In contrast to our findings, homozygosity for this variant was associated with protection against cutaneous leishmaniasis in Syria <xref rid="pone.0060237-Assaf1" ref-type="bibr">[32]</xref> and the presence of this allele, with protection against cytomegalovirus, but not bacterial infections, after orthotopic liver transplantation <xref rid="pone.0060237-deRooij1" ref-type="bibr">[33]</xref>, <xref rid="pone.0060237-deRooij2" ref-type="bibr">[34]</xref>. It was not associated with respiratory tract infections in Dutch children <xref rid="pone.0060237-Ruskamp1" ref-type="bibr">[35]</xref>, nor with invasive pneumococcal disease <xref rid="pone.0060237-Chapman1" ref-type="bibr">[36]</xref>, rheumatoid arthritis <xref rid="pone.0060237-Vander1" ref-type="bibr">[37]</xref> and Beh&#231;et&#8217;s disease in Japan <xref rid="pone.0060237-Chen1" ref-type="bibr">[38]</xref>. Interestingly, <italic>FCN2*258S,</italic> also known as <italic>FCN2-C</italic>, has increased N-acetyl-D-glucosamine (GlcNAc) binding capacity <xref rid="pone.0060237-Hummelshoj1" ref-type="bibr">[11]</xref> and <italic>O</italic>-linked GlcNAc moieties constitute a common epitope between cruzipain, a major <italic>T. cruzi</italic> antigen, and either myosin or other cardiac O-GlcNAc-containing proteins <xref rid="pone.0060237-Acosta1" ref-type="bibr">[39]</xref>. Higher GlcNAc binding capacity of this variant may thus correlate with complement activation and destructive deposition of membrane attack complexes (MAC) on muscle tissues of patients with cardiodigestive manifestations. At least for chronic chagasic cardiomyopathy, increased MAC deposition has been observed, in contrast to patients with idiopathic dilated cardiomyopathy or controls <xref rid="pone.0060237-Aiello1" ref-type="bibr">[40]</xref>. Additionally, our study also showed that there are associations between 258S variant and L-ficolin level in the patients. The association between low L-ficolin levels and the <italic>258S</italic> variant has also formerly been observed in other settings: healthy Danish individuals <xref rid="pone.0060237-MuntheFog1" ref-type="bibr">[13]</xref>, Polish children with recurrent infections <xref rid="pone.0060237-Cedzynski1" ref-type="bibr">[12]</xref>, Gabonese malaria patients (but not controls) <xref rid="pone.0060237-Faik1" ref-type="bibr">[16]</xref>, Vietnamese HBV-infected patients and controls <xref rid="pone.0060237-Hoang1" ref-type="bibr">[15]</xref>.</p><p>In conclusion, this is the first report on L-ficolin levels and <italic>FCN2</italic> polymorphisms in patients with chronic CD. Activation of the lectin and alternative complement system is a crucial defense mechanism for the control of <italic>T. cruzi</italic> parasitemia <xref rid="pone.0060237-Cestari1" ref-type="bibr">[7]</xref> and L-ficolin has been shown to bind metacyclic trypomastigotes <xref rid="pone.0060237-Cestari1" ref-type="bibr">[7]</xref>. Decreased levels of L-ficolin in chagasic patients reflect, in part, the higher frequency of the <italic>258S</italic> variant in those with cardiodigestive symptoms. However, since most of the <italic>FCN2</italic> genotypes did not associate with L-ficolin levels, reduction may also be due to the disease process itself, since L-ficolin can bind to <italic>T.cruzi</italic> antigens <xref rid="pone.0060237-Cestari1" ref-type="bibr">[7]</xref>, to pentraxin 3 <xref rid="pone.0060237-Ma1" ref-type="bibr">[41]</xref> and to the C-reactive protein <xref rid="pone.0060237-Ng1" ref-type="bibr">[42]</xref>, which might affect circulating levels. In addition, inflammatory activity and the resulting tissue fibrosis could be further exacerbated by the higher capacity of GlcNAc binding to the <italic>258S</italic> variant. L-ficolin levels and consumption could thus be used as markers of disease activity, but further experiments should be performed to prove this hypothesis.</p></sec></body><back><ack><p>The authors dedicate this article to Professor Dr J&#252;rgen FJ Kun (of blessed memory) for all his scientific support and friendship. We thank Andrea Weierich, Viola Galinat, Eman A. Ouf<bold>,</bold> Hoang Van Tong and Olosola Ojurongbe for the excellent technical help. We are also thankful for the staff of the Chagas Ambulatory of the Clinical Hospital of Federal University of Paran&#225; for their friendly collaboration as well as patients for their participation.</p></ack><ref-list><title>References</title><ref id="pone.0060237-Dias1"><label>1</label><mixed-citation publication-type="other">Dias JCP (2008) Eradication of Chagas Disease: What Are Its Possibilities? Report of the Scientific Meeting, Rio de Janeiro, Brazil. Ref Type: Report.</mixed-citation></ref><ref id="pone.0060237-Ribeiro1"><label>2</label><mixed-citation publication-type="journal">
<name><surname>Ribeiro</surname><given-names>AL</given-names></name>, <name><surname>Rocha</surname><given-names>MO</given-names></name> (<year>1998</year>) <article-title>[Indeterminate form of Chagas disease: considerations about diagnosis and prognosis]</article-title>. <source>Rev Soc Bras Med Trop</source>
<volume>31</volume>: <fpage>301</fpage>&#8211;<lpage>314</lpage>.<pub-id pub-id-type="pmid">9612022</pub-id></mixed-citation></ref><ref id="pone.0060237-Dutra1"><label>3</label><mixed-citation publication-type="journal">
<name><surname>Dutra</surname><given-names>WO</given-names></name>, <name><surname>Gollob</surname><given-names>KJ</given-names></name> (<year>2008</year>) <article-title>Current concepts in immunoregulation and pathology of human Chagas disease</article-title>. <source>Curr Opin Infect Dis</source>
<volume>21</volume>: <fpage>287</fpage>&#8211;<lpage>292</lpage>.<pub-id pub-id-type="pmid">18448974</pub-id></mixed-citation></ref><ref id="pone.0060237-Kipnis1"><label>4</label><mixed-citation publication-type="journal">
<name><surname>Kipnis</surname><given-names>TL</given-names></name>, <name><surname>Joiner</surname><given-names>KA</given-names></name>, <name><surname>da Silva</surname><given-names>WD</given-names></name>, <name><surname>Rimoldi</surname><given-names>MT</given-names></name>, <name><surname>Hammer</surname><given-names>CH</given-names></name>, <etal>et al</etal> (<year>1988</year>) <article-title>Identification of membrane components of Trypanosoma cruzi modulators of complement system</article-title>. <source>Mem Inst Oswaldo Cruz</source>
<volume>83</volume> Suppl 1<fpage>571</fpage>&#8211;<lpage>575</lpage>.<pub-id pub-id-type="pmid">2473383</pub-id></mixed-citation></ref><ref id="pone.0060237-MessiasReason1"><label>5</label><mixed-citation publication-type="journal">
<name><surname>Messias-Reason</surname><given-names>IJ</given-names></name>, <name><surname>Urbanetz</surname><given-names>L</given-names></name>, <name><surname>Pereira da</surname><given-names>CC</given-names></name> (<year>2003</year>) <article-title>Complement C3 F and BF S allotypes are risk factors for Chagas disease cardiomyopathy</article-title>. <source>Tissue Antigens</source>
<volume>62</volume>: <fpage>308</fpage>&#8211;<lpage>312</lpage>.<pub-id pub-id-type="pmid">12974797</pub-id></mixed-citation></ref><ref id="pone.0060237-Luz1"><label>6</label><mixed-citation publication-type="journal">
<name><surname>Luz</surname><given-names>PR</given-names></name>, <name><surname>Miyazaki</surname><given-names>MI</given-names></name>, <name><surname>Neto</surname><given-names>NC</given-names></name>, <name><surname>Nisihara</surname><given-names>RM</given-names></name>, <name><surname>Messias-Reason</surname><given-names>IJ</given-names></name> (<year>2010</year>) <article-title>High levels of mannose-binding lectin are associated with the risk of severe cardiomyopathy in chronic Chagas Disease</article-title>. <source>Int J Cardiol</source>
<volume>143</volume>: <fpage>448</fpage>&#8211;<lpage>450</lpage>.<pub-id pub-id-type="pmid">19853314</pub-id></mixed-citation></ref><ref id="pone.0060237-Cestari1"><label>7</label><mixed-citation publication-type="journal">
<name><surname>Cestari</surname><given-names>IS</given-names></name>, <name><surname>Krarup</surname><given-names>A</given-names></name>, <name><surname>Sim</surname><given-names>RB</given-names></name>, <name><surname>Inal</surname><given-names>JM</given-names></name>, <name><surname>Ramirez</surname><given-names>MI</given-names></name> (<year>2009</year>) <article-title>Role of early lectin pathway activation in the complement-mediated killing of Trypanosoma cruzi</article-title>. <source>Mol Immunol</source>
<volume>47</volume>: <fpage>426</fpage>&#8211;<lpage>437</lpage>.<pub-id pub-id-type="pmid">19783051</pub-id></mixed-citation></ref><ref id="pone.0060237-Boldt1"><label>8</label><mixed-citation publication-type="journal">
<name><surname>Boldt</surname><given-names>AB</given-names></name>, <name><surname>Luz</surname><given-names>PR</given-names></name>, <name><surname>Messias-Reason</surname><given-names>IJ</given-names></name> (<year>2011</year>) <article-title>MASP2 haplotypes are associated with high risk of cardiomyopathy in chronic Chagas disease</article-title>. <source>Clin Immunol</source>
<volume>140</volume>: <fpage>63</fpage>&#8211;<lpage>70</lpage>.<pub-id pub-id-type="pmid">21489885</pub-id></mixed-citation></ref><ref id="pone.0060237-Runza1"><label>9</label><mixed-citation publication-type="journal">
<name><surname>Runza</surname><given-names>VL</given-names></name>, <name><surname>Schwaeble</surname><given-names>W</given-names></name>, <name><surname>Mannel</surname><given-names>DN</given-names></name> (<year>2008</year>) <article-title>Ficolins: novel pattern recognition molecules of the innate immune response</article-title>. <source>Immunobiology</source>
<volume>213</volume>: <fpage>297</fpage>&#8211;<lpage>306</lpage>.<pub-id pub-id-type="pmid">18406375</pub-id></mixed-citation></ref><ref id="pone.0060237-Jensen1"><label>10</label><mixed-citation publication-type="journal">
<name><surname>Jensen</surname><given-names>ML</given-names></name>, <name><surname>Honore</surname><given-names>C</given-names></name>, <name><surname>Hummelshoj</surname><given-names>T</given-names></name>, <name><surname>Hansen</surname><given-names>BE</given-names></name>, <name><surname>Madsen</surname><given-names>HO</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Ficolin-2 recognizes DNA and participates in the clearance of dying host cells</article-title>. <source>Mol Immunol</source>
<volume>44</volume>: <fpage>856</fpage>&#8211;<lpage>865</lpage>.<pub-id pub-id-type="pmid">16730064</pub-id></mixed-citation></ref><ref id="pone.0060237-Hummelshoj1"><label>11</label><mixed-citation publication-type="journal">
<name><surname>Hummelshoj</surname><given-names>T</given-names></name>, <name><surname>Munthe-Fog</surname><given-names>L</given-names></name>, <name><surname>Madsen</surname><given-names>HO</given-names></name>, <name><surname>Fujita</surname><given-names>T</given-names></name>, <name><surname>Matsushita</surname><given-names>M</given-names></name>, <etal>et al</etal> (<year>2005</year>) <article-title>Polymorphisms in the FCN2 gene determine serum variation and function of Ficolin-2</article-title>. <source>Hum Mol Genet</source>
<volume>14</volume>: <fpage>1651</fpage>&#8211;<lpage>1658</lpage>.<pub-id pub-id-type="pmid">15879437</pub-id></mixed-citation></ref><ref id="pone.0060237-Cedzynski1"><label>12</label><mixed-citation publication-type="journal">
<name><surname>Cedzynski</surname><given-names>M</given-names></name>, <name><surname>Nuytinck</surname><given-names>L</given-names></name>, <name><surname>Atkinson</surname><given-names>AP</given-names></name>, <name><surname>St</surname><given-names>SA</given-names></name>, <name><surname>Zeman</surname><given-names>K</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Extremes of L-ficolin concentration in children with recurrent infections are associated with single nucleotide polymorphisms in the FCN2 gene</article-title>. <source>Clin Exp Immunol</source>
<volume>150</volume>: <fpage>99</fpage>&#8211;<lpage>104</lpage>.<pub-id pub-id-type="pmid">17680820</pub-id></mixed-citation></ref><ref id="pone.0060237-MuntheFog1"><label>13</label><mixed-citation publication-type="journal">
<name><surname>Munthe-Fog</surname><given-names>L</given-names></name>, <name><surname>Hummelshoj</surname><given-names>T</given-names></name>, <name><surname>Hansen</surname><given-names>BE</given-names></name>, <name><surname>Koch</surname><given-names>C</given-names></name>, <name><surname>Madsen</surname><given-names>HO</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>The impact of FCN2 polymorphisms and haplotypes on the Ficolin-2 serum levels</article-title>. <source>Scand J Immunol</source>
<volume>65</volume>: <fpage>383</fpage>&#8211;<lpage>392</lpage>.<pub-id pub-id-type="pmid">17386030</pub-id></mixed-citation></ref><ref id="pone.0060237-deMessiasReason1"><label>14</label><mixed-citation publication-type="journal">
<name><surname>de Messias-Reason</surname><given-names>I</given-names></name>, <name><surname>Kremsner</surname><given-names>PG</given-names></name>, <name><surname>Kun</surname><given-names>JF</given-names></name> (<year>2009</year>) <article-title>Functional haplotypes that produce normal ficolin-2 levels protect against clinical leprosy</article-title>. <source>J Infect Dis</source>
<volume>199</volume>: <fpage>801</fpage>&#8211;<lpage>804</lpage>.<pub-id pub-id-type="pmid">19434912</pub-id></mixed-citation></ref><ref id="pone.0060237-Hoang1"><label>15</label><mixed-citation publication-type="journal">
<name><surname>Hoang</surname><given-names>TV</given-names></name>, <name><surname>Toan</surname><given-names>NL</given-names></name>, <name><surname>Song</surname><given-names>lH</given-names></name>, <name><surname>Ouf</surname><given-names>EA</given-names></name>, <name><surname>Bock</surname><given-names>CT</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Ficolin-2 levels and FCN2 haplotypes influence hepatitis B infection outcome in Vietnamese patients</article-title>. <source>PLoS One</source>
<volume>6</volume>: <fpage>e28113</fpage>.<pub-id pub-id-type="pmid">22140517</pub-id></mixed-citation></ref><ref id="pone.0060237-Faik1"><label>16</label><mixed-citation publication-type="journal">
<name><surname>Faik</surname><given-names>I</given-names></name>, <name><surname>Oyedeji</surname><given-names>SI</given-names></name>, <name><surname>Idris</surname><given-names>Z</given-names></name>, <name><surname>de Messias-Reason</surname><given-names>IJ</given-names></name>, <name><surname>Lell</surname><given-names>B</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Ficolin-2 levels and genetic polymorphisms of FCN2 in malaria</article-title>. <source>Hum Immunol</source>
<volume>72</volume>: <fpage>74</fpage>&#8211;<lpage>79</lpage>.<pub-id pub-id-type="pmid">20937340</pub-id></mixed-citation></ref><ref id="pone.0060237-Ouf1"><label>17</label><mixed-citation publication-type="journal">
<name><surname>Ouf</surname><given-names>EA</given-names></name>, <name><surname>Ojurongbe</surname><given-names>O</given-names></name>, <name><surname>Akindele</surname><given-names>AA</given-names></name>, <name><surname>Sina-Agbaje</surname><given-names>OR</given-names></name>, <name><surname>Van</surname><given-names>TH</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Ficolin-2 levels and FCN2 genetic polymorphisms as a susceptibility factor in schistosomiasis</article-title>. <source>J Infect Dis</source>
<volume>206</volume>: <fpage>562</fpage>&#8211;<lpage>570</lpage>.<pub-id pub-id-type="pmid">22693230</pub-id></mixed-citation></ref><ref id="pone.0060237-MessiasReason2"><label>18</label><mixed-citation publication-type="journal">
<name><surname>Messias-Reason</surname><given-names>IJ</given-names></name>, <name><surname>Schafranski</surname><given-names>MD</given-names></name>, <name><surname>Kremsner</surname><given-names>PG</given-names></name>, <name><surname>Kun</surname><given-names>JF</given-names></name> (<year>2009</year>) <article-title>Ficolin 2 (FCN2) functional polymorphisms and the risk of rheumatic fever and rheumatic heart disease</article-title>. <source>Clin Exp Immunol</source>
<volume>157</volume>: <fpage>395</fpage>&#8211;<lpage>399</lpage>.<pub-id pub-id-type="pmid">19664148</pub-id></mixed-citation></ref><ref id="pone.0060237-Cedzynski2"><label>19</label><mixed-citation publication-type="journal">
<name><surname>Cedzynski</surname><given-names>M</given-names></name>, <name><surname>Atkinson</surname><given-names>AP</given-names></name>, <name><surname>St</surname><given-names>SA</given-names></name>, <name><surname>MacDonald</surname><given-names>SL</given-names></name>, <name><surname>Szala</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>L-ficolin (ficolin-2) insufficiency is associated with combined allergic and infectious respiratory disease in children</article-title>. <source>Mol Immunol</source>
<volume>47</volume>: <fpage>415</fpage>&#8211;<lpage>419</lpage>.<pub-id pub-id-type="pmid">19767106</pub-id></mixed-citation></ref><ref id="pone.0060237-Swierzko1"><label>20</label><mixed-citation publication-type="journal">
<name><surname>Swierzko</surname><given-names>AS</given-names></name>, <name><surname>Atkinson</surname><given-names>AP</given-names></name>, <name><surname>Cedzynski</surname><given-names>M</given-names></name>, <name><surname>MacDonald</surname><given-names>SL</given-names></name>, <name><surname>Szala</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Two factors of the lectin pathway of complement, l-ficolin and mannan-binding lectin, and their associations with prematurity, low birthweight and infections in a large cohort of Polish neonates</article-title>. <source>Mol Immunol</source>
<volume>46</volume>: <fpage>551</fpage>&#8211;<lpage>558</lpage>.<pub-id pub-id-type="pmid">18950864</pub-id></mixed-citation></ref><ref id="pone.0060237-Matsushita1"><label>21</label><mixed-citation publication-type="journal">
<name><surname>Matsushita</surname><given-names>M</given-names></name>, <name><surname>Fujita</surname><given-names>T</given-names></name> (<year>2002</year>) <article-title>The role of ficolins in innate immunity</article-title>. <source>Immunobiology</source>
<volume>205</volume>: <fpage>490</fpage>&#8211;<lpage>497</lpage>.<pub-id pub-id-type="pmid">12396010</pub-id></mixed-citation></ref><ref id="pone.0060237-Krarup1"><label>22</label><mixed-citation publication-type="journal">
<name><surname>Krarup</surname><given-names>A</given-names></name>, <name><surname>Mitchell</surname><given-names>DA</given-names></name>, <name><surname>Sim</surname><given-names>RB</given-names></name> (<year>2008</year>) <article-title>Recognition of acetylated oligosaccharides by human L-ficolin</article-title>. <source>Immunol Lett</source>
<volume>118</volume>: <fpage>152</fpage>&#8211;<lpage>156</lpage>.<pub-id pub-id-type="pmid">18486240</pub-id></mixed-citation></ref><ref id="pone.0060237-Krarup2"><label>23</label><mixed-citation publication-type="journal">
<name><surname>Krarup</surname><given-names>A</given-names></name>, <name><surname>Thiel</surname><given-names>S</given-names></name>, <name><surname>Hansen</surname><given-names>A</given-names></name>, <name><surname>Fujita</surname><given-names>T</given-names></name>, <name><surname>Jensenius</surname><given-names>JC</given-names></name> (<year>2004</year>) <article-title>L-ficolin is a pattern recognition molecule specific for acetyl groups</article-title>. <source>J Biol Chem</source>
<volume>279</volume>: <fpage>47513</fpage>&#8211;<lpage>47519</lpage>.<pub-id pub-id-type="pmid">15331601</pub-id></mixed-citation></ref><ref id="pone.0060237-BrazilianConsensusonChagas1"><label>24</label><mixed-citation publication-type="journal">
<name><surname>[Brazilian Consensus on Chagas</surname><given-names>disease]</given-names></name> (<year>2005</year>) <article-title>Rev Soc Bras Med Trop</article-title>. <volume>38</volume> Suppl 3<fpage>7</fpage>&#8211;<lpage>29</lpage>.</mixed-citation></ref><ref id="pone.0060237-Boldt2"><label>25</label><mixed-citation publication-type="journal">
<name><surname>Boldt</surname><given-names>AB</given-names></name>, <name><surname>Culpi</surname><given-names>L</given-names></name>, <name><surname>Tsuneto</surname><given-names>LT</given-names></name>, <name><surname>de Souza</surname><given-names>IR</given-names></name>, <name><surname>Kun</surname><given-names>JF</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Diversity of the MBL2 gene in various Brazilian populations and the case of selection at the mannose-binding lectin locus</article-title>. <source>Hum Immunol</source>
<volume>67</volume>: <fpage>722</fpage>&#8211;<lpage>734</lpage>.<pub-id pub-id-type="pmid">17002903</pub-id></mixed-citation></ref><ref id="pone.0060237-Ojurongbe1"><label>26</label><mixed-citation publication-type="journal">
<name><surname>Ojurongbe</surname><given-names>O</given-names></name>, <name><surname>Ouf</surname><given-names>EA</given-names></name>, <name><surname>Van</surname><given-names>TH</given-names></name>, <name><surname>Toan</surname><given-names>NL</given-names></name>, <name><surname>Song</surname><given-names>lH</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Reliable and rapid characterization of functional FCN2 gene variants reveals diverse geographical patterns</article-title>. <source>BMC Med Genet</source>
<volume>13</volume>: <fpage>37</fpage>.<pub-id pub-id-type="pmid">22594803</pub-id></mixed-citation></ref><ref id="pone.0060237-Boldt3"><label>27</label><mixed-citation publication-type="journal">
<name><surname>Boldt</surname><given-names>AB</given-names></name>, <name><surname>Petzl-Erler</surname><given-names>ML</given-names></name> (<year>2002</year>) <article-title>A new strategy for mannose-binding lectin gene haplotyping</article-title>. <source>Hum Mutat</source>
<volume>19</volume>: <fpage>296</fpage>&#8211;<lpage>306</lpage>.<pub-id pub-id-type="pmid">11857747</pub-id></mixed-citation></ref><ref id="pone.0060237-Excoffier1"><label>28</label><mixed-citation publication-type="journal">
<name><surname>Excoffier</surname><given-names>L</given-names></name>, <name><surname>Laval</surname><given-names>G</given-names></name>, <name><surname>Schneider</surname><given-names>S</given-names></name> (<year>2005</year>) <article-title>Arlequin (version 3.0): an integrated software package for population genetics data analysis</article-title>. <source>Evol Bioinform Online</source>
<volume>1</volume>: <fpage>47</fpage>&#8211;<lpage>50</lpage>.</mixed-citation></ref><ref id="pone.0060237-Kilpatrick1"><label>29</label><mixed-citation publication-type="journal">
<name><surname>Kilpatrick</surname><given-names>DC</given-names></name>, <name><surname>Fujita</surname><given-names>T</given-names></name>, <name><surname>Matsushita</surname><given-names>M</given-names></name> (<year>1999</year>) <article-title>P35, an opsonic lectin of the ficolin family, in human blood from neonates, normal adults, and recurrent miscarriage patients</article-title>. <source>Immunol Lett</source>
<volume>67</volume>: <fpage>109</fpage>&#8211;<lpage>112</lpage>.<pub-id pub-id-type="pmid">10232391</pub-id></mixed-citation></ref><ref id="pone.0060237-Sallenbach1"><label>30</label><mixed-citation publication-type="journal">
<name><surname>Sallenbach</surname><given-names>S</given-names></name>, <name><surname>Thiel</surname><given-names>S</given-names></name>, <name><surname>Aebi</surname><given-names>C</given-names></name>, <name><surname>Otth</surname><given-names>M</given-names></name>, <name><surname>Bigler</surname><given-names>S</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Serum concentrations of lectin-pathway components in healthy neonates, children and adults: mannan-binding lectin (MBL), M-, L-, and H-ficolin, and MBL-associated serine protease-2 (MASP-2)</article-title>. <source>Pediatr Allergy Immunol</source>
<volume>22</volume>: <fpage>424</fpage>&#8211;<lpage>430</lpage>.<pub-id pub-id-type="pmid">21226765</pub-id></mixed-citation></ref><ref id="pone.0060237-Haerynck1"><label>31</label><mixed-citation publication-type="journal">
<name><surname>Haerynck</surname><given-names>F</given-names></name>, <name><surname>Van</surname><given-names>SK</given-names></name>, <name><surname>Cattaert</surname><given-names>T</given-names></name>, <name><surname>Loeys</surname><given-names>B</given-names></name>, <name><surname>Van</surname><given-names>DS</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Polymorphisms in the lectin pathway genes as a possible cause of early chronic Pseudomonas aeruginosa colonization in cystic fibrosis patients</article-title>. <source>Hum Immunol</source>
<volume>73</volume>: <fpage>1175</fpage>&#8211;<lpage>1183</lpage>.<pub-id pub-id-type="pmid">22940091</pub-id></mixed-citation></ref><ref id="pone.0060237-Assaf1"><label>32</label><mixed-citation publication-type="journal">
<name><surname>Assaf</surname><given-names>A</given-names></name>, <name><surname>Hoang</surname><given-names>TV</given-names></name>, <name><surname>Faik</surname><given-names>I</given-names></name>, <name><surname>Aebischer</surname><given-names>T</given-names></name>, <name><surname>Kremsner</surname><given-names>PG</given-names></name>, <etal>et al</etal> (<year>2012</year>) <article-title>Genetic evidence of functional ficolin-2 haplotype as susceptibility factor in cutaneous leishmaniasis</article-title>. <source>PLoS One</source>
<volume>7</volume>: <fpage>e34113</fpage>.<pub-id pub-id-type="pmid">22457818</pub-id></mixed-citation></ref><ref id="pone.0060237-deRooij1"><label>33</label><mixed-citation publication-type="journal">
<name><surname>de Rooij</surname><given-names>BJ</given-names></name>, <name><surname>van der Beek</surname><given-names>MT</given-names></name>, <name><surname>van</surname><given-names>HB</given-names></name>, <name><surname>Vossen</surname><given-names>AC</given-names></name>, <name><surname>Rogier Ten</surname><given-names>HW</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>Mannose-binding lectin and ficolin-2 gene polymorphisms predispose to cytomegalovirus (re)infection after orthotopic liver transplantation</article-title>. <source>J Hepatol</source>
<volume>55</volume>: <fpage>800</fpage>&#8211;<lpage>807</lpage>.<pub-id pub-id-type="pmid">21334396</pub-id></mixed-citation></ref><ref id="pone.0060237-deRooij2"><label>34</label><mixed-citation publication-type="journal">
<name><surname>de Rooij</surname><given-names>BJ</given-names></name>, <name><surname>van</surname><given-names>HB</given-names></name>, <name><surname>ten Hove</surname><given-names>WR</given-names></name>, <name><surname>Roos</surname><given-names>A</given-names></name>, <name><surname>Bouwman</surname><given-names>LH</given-names></name>, <etal>et al</etal> (<year>2010</year>) <article-title>Lectin complement pathway gene profile of donor and recipient determine the risk of bacterial infections after orthotopic liver transplantation</article-title>. <source>Hepatology</source>
<volume>52</volume>: <fpage>1100</fpage>&#8211;<lpage>1110</lpage>.<pub-id pub-id-type="pmid">20593422</pub-id></mixed-citation></ref><ref id="pone.0060237-Ruskamp1"><label>35</label><mixed-citation publication-type="journal">
<name><surname>Ruskamp</surname><given-names>JM</given-names></name>, <name><surname>Hoekstra</surname><given-names>MO</given-names></name>, <name><surname>Postma</surname><given-names>DS</given-names></name>, <name><surname>Kerkhof</surname><given-names>M</given-names></name>, <name><surname>Bottema</surname><given-names>RW</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Exploring the role of polymorphisms in ficolin genes in respiratory tract infections in children</article-title>. <source>Clin Exp Immunol</source>
<volume>155</volume>: <fpage>433</fpage>&#8211;<lpage>440</lpage>.<pub-id pub-id-type="pmid">19220833</pub-id></mixed-citation></ref><ref id="pone.0060237-Chapman1"><label>36</label><mixed-citation publication-type="journal">
<name><surname>Chapman</surname><given-names>SJ</given-names></name>, <name><surname>Vannberg</surname><given-names>FO</given-names></name>, <name><surname>Khor</surname><given-names>CC</given-names></name>, <name><surname>Segal</surname><given-names>S</given-names></name>, <name><surname>Moore</surname><given-names>CE</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Functional polymorphisms in the FCN2 gene are not associated with invasive pneumococcal disease</article-title>. <source>Mol Immunol</source>
<volume>44</volume>: <fpage>3267</fpage>&#8211;<lpage>3270</lpage>.<pub-id pub-id-type="pmid">17382393</pub-id></mixed-citation></ref><ref id="pone.0060237-Vander1"><label>37</label><mixed-citation publication-type="journal">
<name><surname>Vander</surname><given-names>CB</given-names></name>, <name><surname>Nuytinck</surname><given-names>L</given-names></name>, <name><surname>Boullart</surname><given-names>L</given-names></name>, <name><surname>Elewaut</surname><given-names>D</given-names></name>, <name><surname>Waegeman</surname><given-names>W</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>Polymorphisms in the ficolin 1 gene (FCN1) are associated with susceptibility to the development of rheumatoid arthritis</article-title>. <source>Rheumatology (Oxford)</source>
<volume>46</volume>: <fpage>1792</fpage>&#8211;<lpage>1795</lpage>.<pub-id pub-id-type="pmid">18032536</pub-id></mixed-citation></ref><ref id="pone.0060237-Chen1"><label>38</label><mixed-citation publication-type="journal">
<name><surname>Chen</surname><given-names>X</given-names></name>, <name><surname>Katoh</surname><given-names>Y</given-names></name>, <name><surname>Nakamura</surname><given-names>K</given-names></name>, <name><surname>Oyama</surname><given-names>N</given-names></name>, <name><surname>Kaneko</surname><given-names>F</given-names></name>, <etal>et al</etal> (<year>2006</year>) <article-title>Single nucleotide polymorphisms of Ficolin 2 gene in Behcet&#8217;s disease</article-title>. <source>J Dermatol Sci</source>
<volume>43</volume>: <fpage>201</fpage>&#8211;<lpage>205</lpage>.<pub-id pub-id-type="pmid">16839748</pub-id></mixed-citation></ref><ref id="pone.0060237-Acosta1"><label>39</label><mixed-citation publication-type="journal">
<name><surname>Acosta</surname><given-names>DM</given-names></name>, <name><surname>Soprano</surname><given-names>LL</given-names></name>, <name><surname>Ferrero</surname><given-names>M</given-names></name>, <name><surname>Landoni</surname><given-names>M</given-names></name>, <name><surname>Esteva</surname><given-names>MI</given-names></name>, <etal>et al</etal> (<year>2011</year>) <article-title>A striking common O-linked N-acetylglucosaminyl moiety between cruzipain and myosin</article-title>. <source>Parasite Immunol</source>
<volume>33</volume>: <fpage>363</fpage>&#8211;<lpage>370</lpage>.<pub-id pub-id-type="pmid">21426361</pub-id></mixed-citation></ref><ref id="pone.0060237-Aiello1"><label>40</label><mixed-citation publication-type="journal">
<name><surname>Aiello</surname><given-names>VD</given-names></name>, <name><surname>Reis</surname><given-names>MM</given-names></name>, <name><surname>Benvenuti</surname><given-names>LA</given-names></name>, <name><surname>Higuchi</surname><given-names>ML</given-names></name>, <name><surname>Ramires</surname><given-names>JA</given-names></name>, <etal>et al</etal> (<year>2002</year>) <article-title>A possible role for complement in the pathogenesis of chronic chagasic cardiomyopathy</article-title>. <source>J Pathol</source>
<volume>197</volume>: <fpage>224</fpage>&#8211;<lpage>229</lpage>.<pub-id pub-id-type="pmid">12015747</pub-id></mixed-citation></ref><ref id="pone.0060237-Ma1"><label>41</label><mixed-citation publication-type="journal">
<name><surname>Ma</surname><given-names>YJ</given-names></name>, <name><surname>Doni</surname><given-names>A</given-names></name>, <name><surname>Hummelshoj</surname><given-names>T</given-names></name>, <name><surname>Honore</surname><given-names>C</given-names></name>, <name><surname>Bastone</surname><given-names>A</given-names></name>, <etal>et al</etal> (<year>2009</year>) <article-title>Synergy between ficolin-2 and pentraxin 3 boosts innate immune recognition and complement deposition</article-title>. <source>J Biol Chem</source>
<volume>284</volume>: <fpage>28263</fpage>&#8211;<lpage>28275</lpage>.<pub-id pub-id-type="pmid">19632990</pub-id></mixed-citation></ref><ref id="pone.0060237-Ng1"><label>42</label><mixed-citation publication-type="journal">
<name><surname>Ng</surname><given-names>PM</given-names></name>, <name><surname>Le</surname><given-names>SA</given-names></name>, <name><surname>Lee</surname><given-names>CM</given-names></name>, <name><surname>Tan</surname><given-names>NS</given-names></name>, <name><surname>Lu</surname><given-names>J</given-names></name>, <etal>et al</etal> (<year>2007</year>) <article-title>C-reactive protein collaborates with plasma lectins to boost immune response against bacteria</article-title>. <source>EMBO J</source>
<volume>26</volume>: <fpage>3431</fpage>&#8211;<lpage>3440</lpage>.<pub-id pub-id-type="pmid">17581635</pub-id></mixed-citation></ref></ref-list></back></article>